In August 2010 Bexion Pharmaceuticals was selected by the National Cancer Institute (NCI) for a research collaboration to study Bexion’s first-in-class nanotherapy treatment for solid tumors. The intent of these studies helped Bexion to support its filings with the U.S. Food and Drug Administration (FDA). The cost of these studies was paid for by the Nanotechnology Characterization Laboratory (NCL). The agreement is part of the NCI’s Advanced Technology Partnerships Initiative, which seeks to accelerate the delivery of new products to cancer patients.
National Cancer Institute
Nanotechnology Characterization Laboratory